We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLT
426
DELISTED
CATALENT, INC.
CTLT
| $4.39M | 0.03% |
40,616
+30,046
| +284% | +$3.22M |
|
|
FLY
427
DELISTED
Fly Leasing Limited
FLY
| $4.39M | 0.03% |
+259,121
| New | +$4.38M |
|
428
Outset Medical
OM
$80.1M
| $4.38M | 0.03% |
5,837
+2,414
| +71% | +$1.85M |
|
|
429
Allstate
ALL
$67.3B
| $4.37M | 0.03% |
33,516
-404,347
| -92% | -$52.2M |
|
430
Generac Holdings
GNRC
$11.6B
| $4.37M | 0.03% |
10,517
-99,008
| -90% | -$33.2M |
|
431
Yum China
YUMC
$15.3B
| $4.35M | 0.03% |
65,600
+5,218
| +9% | +$333K |
|
432
Assembly Biosciences
ASMB
$513M
| $4.32M | 0.03% |
92,813
-1,899
| -2% | -$94.1K |
|
433
Keros Therapeutics
KROS
$202M
| $4.31M | 0.03% |
+101,409
| New | +$5.49M |
|
434
Snowflake
SNOW
$94.6B
| $4.26M | 0.03% |
+17,637
| New | +$4.1M |
|
|
ISEE
435
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.26M | 0.03% |
+675,575
| New | +$4.36M |
|
436
Old Dominion Freight Line
ODFL
$47.2B
| $4.24M | 0.03% |
33,388
-35,010
| -51% | -$4.49M |
|
437
iShares MSCI Canada ETF
EWC
$6.13B
| $4.22M | 0.03% |
113,314
-2,277
| -2% | -$83.3K |
|
438
OrthoPediatrics
KIDS
$509M
| $4.19M | 0.03% |
+66,369
| New | +$3.81M |
|
439
Baxter International
BAX
$12.1B
| $4.16M | 0.03% |
51,699
-69,647
| -57% | -$5.84M |
|
440
Zoom
ZM
$26.7B
| $4.15M | 0.03% |
10,731
+1,403
| +15% | +$467K |
|
441
Kulicke & Soffa
KLIC
$5.14B
| $4.13M | 0.03% |
+67,421
| New | +$3.63M |
|
442
Roper Technologies
ROP
$37.1B
| $4.09M | 0.03% |
8,701
-8,357
| -49% | -$3.69M |
|
|
PVLA
443
Palvella Therapeutics
PVLA
$2.03B
| $4.07M | 0.03% |
13,273
-15,136
| -53% | -$3.32M |
|
|
BLDP
444
Ballard Power Systems
BLDP
$865M
| $4.06M | 0.03% |
224,096
+42,155
| +23% | +$784K |
|
445
CDW
CDW
$17.6B
| $3.97M | 0.03% |
22,706
-13,240
| -37% | -$2.28M |
|
|
RNAM
446
DELISTED
Avidity Biosciences
RNAM
| $3.95M | 0.03% |
159,988
+140,491
| +721% | +$3.27M |
|
447
Martin Marietta Materials
MLM
$34.3B
| $3.94M | 0.03% |
11,213
-718
| -6% | -$256K |
|
448
Viatris
VTRS
$20.5B
| $3.94M | 0.03% |
275,840
+19,290
| +8% | +$279K |
|
449
Chevron
CVX
$378B
| $3.94M | 0.03% |
37,628
+5,175
| +16% | +$546K |
|
450
Honeywell
HON
$77.9B
| $3.94M | 0.03% |
19,059
-492
| -3% | -$104K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.